first-line treatment for severe dlbcl-ci cases that are not pat. the r-chop regiment or similar immunochemotherapeutic regimen (e.g. epoch, i.e. rituximab plus etoposide, prednisolone, oncovin, cyclophosphamide, and hydroxydaunorubicin) may prove useful for treating dlbcl-ci. new treatment studies an interventional phase ii clinical trial testing the effectiveness and safety of r-chop versus r-chop plus lenalidomide (unclear mechanism of action) in 570 previously untreated participants with various forms of dlbcl, including dlbcl-ci, has finished recruitment of participants. it has an estimated study completion date of august 3, 2022. a phase ii clinical trial is recruiting individuals to study how well nivolumab with or without varlilumab works in treating patients with aggressive b-cell lymphomas, including dlbcl-ci, that have come back, or do not respond, to immunotherapy with either one of these monoclonal antibodies. a phase i clinical trial is recruiting individuals to study the side effects and efficacy of cd19/cd22 chimeric antigen receptor t cells (i.e. t-cells from a donor patent are obtained, engineered to attack cells that express cd19 or cd22, and then injected back into the donor) when given together with chemotherapy in treating patients with dlbcl, including dlbcl-ci, or b-cell acute lymphoblastic leukemia. only individuals whose neoblastic b-cells express the cd19 cell surface protein are eligible to enter this study.